Evaluation of teicoplanin concentrations and safety analysis in neonates

Takaaki Yamada, Toshio Kubota, Masako Nakamura, Masayuki Ochiai, Mahoro Yonezawa, Takahisa Yano, takehiro kawashiri, Nobuaki Egashira, Toshiro Hara, Satohiro Masuda

研究成果: ジャーナルへの寄稿記事

6 引用 (Scopus)

抄録

The aims of this study were (i) to evaluate the relationship between teicoplanin (TEIC) dosage and subsequent trough concentration, (ii) to investigate factors that affect TEIC serum concentration fluctuations and (iii) to examine the association between serum concentration of TEIC and adverse reactions in neonates. A total of 37 eligible neonates (<28 days of age) treated with TEIC from 2008-2012 were included in this study. The median trough concentration in the loading dose regimen of >12-16 mg/kg on Day 1, followed by >6-8 mg/kg every 24 h (q24 h) was 19.6 μg/mL on Day 3 or 4, and the median trough concentration in the maintenance dose regimen of >6-8 mg/kg q24 h was 18.5 μg/mL at steady-state. There were significant correlations between serum creatinine and concentration/dose (C/D) ratio (r = 0.475, P = 0.019), body weight and C/D ratio (r = -0.425, P = 0.038) and corrected gestational age and C/D ratio (r = -0.482, P = 0.017) after administering the loading dose. The incidence of hepatic dysfunction, renal impairment and thrombocytopenia was 14.8%, 20.0% and 14.8%, respectively. There was no significant difference in the incidence of adverse reactions between the trough concentration <20 μg/mL and ≥20 μg/mL groups. These data suggest that the recommended TEIC dosage for neonates is appropriate to achieve and maintain a trough concentration range of 15-30 μg/mL, and it is possible to set the target trough concentration at ≥20 μg/mL for deep-seated infections such as endocarditis, bone and joint infections, and osteomyelitis.

元の言語英語
ページ(範囲)458-462
ページ数5
ジャーナルInternational Journal of Antimicrobial Agents
44
発行部数5
DOI
出版物ステータス出版済み - 1 1 2014

Fingerprint

Teicoplanin
Safety
Serum
Incidence
Osteomyelitis
Endocarditis
Infection
Thrombocytopenia
Gestational Age
Creatinine
Joints
Body Weight
Kidney
Bone and Bones
Liver

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

これを引用

Evaluation of teicoplanin concentrations and safety analysis in neonates. / Yamada, Takaaki; Kubota, Toshio; Nakamura, Masako; Ochiai, Masayuki; Yonezawa, Mahoro; Yano, Takahisa; kawashiri, takehiro; Egashira, Nobuaki; Hara, Toshiro; Masuda, Satohiro.

:: International Journal of Antimicrobial Agents, 巻 44, 番号 5, 01.01.2014, p. 458-462.

研究成果: ジャーナルへの寄稿記事

Yamada, Takaaki ; Kubota, Toshio ; Nakamura, Masako ; Ochiai, Masayuki ; Yonezawa, Mahoro ; Yano, Takahisa ; kawashiri, takehiro ; Egashira, Nobuaki ; Hara, Toshiro ; Masuda, Satohiro. / Evaluation of teicoplanin concentrations and safety analysis in neonates. :: International Journal of Antimicrobial Agents. 2014 ; 巻 44, 番号 5. pp. 458-462.
@article{28f76f6aba714935a9107b5e35fed7f2,
title = "Evaluation of teicoplanin concentrations and safety analysis in neonates",
abstract = "The aims of this study were (i) to evaluate the relationship between teicoplanin (TEIC) dosage and subsequent trough concentration, (ii) to investigate factors that affect TEIC serum concentration fluctuations and (iii) to examine the association between serum concentration of TEIC and adverse reactions in neonates. A total of 37 eligible neonates (<28 days of age) treated with TEIC from 2008-2012 were included in this study. The median trough concentration in the loading dose regimen of >12-16 mg/kg on Day 1, followed by >6-8 mg/kg every 24 h (q24 h) was 19.6 μg/mL on Day 3 or 4, and the median trough concentration in the maintenance dose regimen of >6-8 mg/kg q24 h was 18.5 μg/mL at steady-state. There were significant correlations between serum creatinine and concentration/dose (C/D) ratio (r = 0.475, P = 0.019), body weight and C/D ratio (r = -0.425, P = 0.038) and corrected gestational age and C/D ratio (r = -0.482, P = 0.017) after administering the loading dose. The incidence of hepatic dysfunction, renal impairment and thrombocytopenia was 14.8{\%}, 20.0{\%} and 14.8{\%}, respectively. There was no significant difference in the incidence of adverse reactions between the trough concentration <20 μg/mL and ≥20 μg/mL groups. These data suggest that the recommended TEIC dosage for neonates is appropriate to achieve and maintain a trough concentration range of 15-30 μg/mL, and it is possible to set the target trough concentration at ≥20 μg/mL for deep-seated infections such as endocarditis, bone and joint infections, and osteomyelitis.",
author = "Takaaki Yamada and Toshio Kubota and Masako Nakamura and Masayuki Ochiai and Mahoro Yonezawa and Takahisa Yano and takehiro kawashiri and Nobuaki Egashira and Toshiro Hara and Satohiro Masuda",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.ijantimicag.2014.07.005",
language = "English",
volume = "44",
pages = "458--462",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Evaluation of teicoplanin concentrations and safety analysis in neonates

AU - Yamada, Takaaki

AU - Kubota, Toshio

AU - Nakamura, Masako

AU - Ochiai, Masayuki

AU - Yonezawa, Mahoro

AU - Yano, Takahisa

AU - kawashiri, takehiro

AU - Egashira, Nobuaki

AU - Hara, Toshiro

AU - Masuda, Satohiro

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The aims of this study were (i) to evaluate the relationship between teicoplanin (TEIC) dosage and subsequent trough concentration, (ii) to investigate factors that affect TEIC serum concentration fluctuations and (iii) to examine the association between serum concentration of TEIC and adverse reactions in neonates. A total of 37 eligible neonates (<28 days of age) treated with TEIC from 2008-2012 were included in this study. The median trough concentration in the loading dose regimen of >12-16 mg/kg on Day 1, followed by >6-8 mg/kg every 24 h (q24 h) was 19.6 μg/mL on Day 3 or 4, and the median trough concentration in the maintenance dose regimen of >6-8 mg/kg q24 h was 18.5 μg/mL at steady-state. There were significant correlations between serum creatinine and concentration/dose (C/D) ratio (r = 0.475, P = 0.019), body weight and C/D ratio (r = -0.425, P = 0.038) and corrected gestational age and C/D ratio (r = -0.482, P = 0.017) after administering the loading dose. The incidence of hepatic dysfunction, renal impairment and thrombocytopenia was 14.8%, 20.0% and 14.8%, respectively. There was no significant difference in the incidence of adverse reactions between the trough concentration <20 μg/mL and ≥20 μg/mL groups. These data suggest that the recommended TEIC dosage for neonates is appropriate to achieve and maintain a trough concentration range of 15-30 μg/mL, and it is possible to set the target trough concentration at ≥20 μg/mL for deep-seated infections such as endocarditis, bone and joint infections, and osteomyelitis.

AB - The aims of this study were (i) to evaluate the relationship between teicoplanin (TEIC) dosage and subsequent trough concentration, (ii) to investigate factors that affect TEIC serum concentration fluctuations and (iii) to examine the association between serum concentration of TEIC and adverse reactions in neonates. A total of 37 eligible neonates (<28 days of age) treated with TEIC from 2008-2012 were included in this study. The median trough concentration in the loading dose regimen of >12-16 mg/kg on Day 1, followed by >6-8 mg/kg every 24 h (q24 h) was 19.6 μg/mL on Day 3 or 4, and the median trough concentration in the maintenance dose regimen of >6-8 mg/kg q24 h was 18.5 μg/mL at steady-state. There were significant correlations between serum creatinine and concentration/dose (C/D) ratio (r = 0.475, P = 0.019), body weight and C/D ratio (r = -0.425, P = 0.038) and corrected gestational age and C/D ratio (r = -0.482, P = 0.017) after administering the loading dose. The incidence of hepatic dysfunction, renal impairment and thrombocytopenia was 14.8%, 20.0% and 14.8%, respectively. There was no significant difference in the incidence of adverse reactions between the trough concentration <20 μg/mL and ≥20 μg/mL groups. These data suggest that the recommended TEIC dosage for neonates is appropriate to achieve and maintain a trough concentration range of 15-30 μg/mL, and it is possible to set the target trough concentration at ≥20 μg/mL for deep-seated infections such as endocarditis, bone and joint infections, and osteomyelitis.

UR - http://www.scopus.com/inward/record.url?scp=84908455019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908455019&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2014.07.005

DO - 10.1016/j.ijantimicag.2014.07.005

M3 - Article

VL - 44

SP - 458

EP - 462

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 5

ER -